TO THE EDITOR
We describe the rare coincidence of hypertriploid chromosome number and aberrant coexpression of the lymphoid marker CD5 in a patient with AML FAB M0. The patient was successfully treated with an allogeneic peripheral blood stem cell transplantation (PBSCT) from a sibling donor.
Case report
A 30-year-old woman was admitted to our department in June 2002 with a history of 4 weeks of infection (cold), fever (391C) and tiredness. Physical examination of the young woman showed no pathological signs. Laboratory data showed anaemia (Hb 7.1 g/dl), normal thrombocyte count (169 Gpt/l) and weak leucocytosis (11.6 Gpt/l) with a frequency of blasts in the peripheral blood of 92%. Bone marrow aspiration showed 65% of marrow cells to be leukaemic blasts. Cytochemistry examination of the bone marrow and peripheral blood were negative for myeloperoxidase, anaphthol AS-D chloroacetate esterase and periodic acid-Schiff staining. Flow cytometry was performed using a broad panel of antibodies including CD3, CD4, CD5, CD7, CD13, CD14, CD15, CD19, CD33, CD34, CD45 and HLA-DR (Becton Dickinson, BD, USA). 1 It revealed positivity of the blast cells for CD34, CD15 and CD33. Moreover, the blasts were positive for the lymphatic marker CD5 (see Figure 1 ) and negative for additionally lineage-associated markers CD13, CD19, CD22, CD79a and CD3. Owing to the negativity of cytochemistry and the expression of two myeloid markers vs one lymphatic marker in the immunphenotype of the blast, we confirmed the diagnosis AML-M0 with the coexpression of CD5. The cytogenetic analysis was performed using the R-Cbanding technique. 2 Karyotypes were described according to the International System for Human Cytogenetics Nomenclature. 3 In all, 10 metaphases were analysed. The cytogenetic analysis showed a chromosome number amounting to hypertriploid; the number ranged from 77 to 79. The tetrasomy 4, 6, 14, 19, 20, 21 and 22 occurred in all metaphases, whereas the tetrasomy 8 and 18 were observed only in five mitoses (see Figure 2) . No structural changes were seen.
The patient received an induction chemotherapy consisting of cytarabine (2 Â 1000 mg/m 2 days 1, 3, 5, 7) and idarubicine (12 mg/ m 2 days 1-3) leading to complete remission. Owing to complex cytogenetic aberration (changes of three and more chromosomes) as a marker for high risk for relapse, a PBSCT from an HLA-identical brother was performed in first remission. The conditioning regimen consisted of total body irradiation (2 Â 2 Gy days À8 to À6, with shielding of the lung) and cytarabine (2 Â 3000 mg/m 2 days À5 to À2). The graft contained 4.6 Â 10 6 CD34-positive blood stem cells. After 14 days, the neutrophils were 41 Gpt/l. Examination of bone marrow after the transplantation showed a complete chimerism and a normal male karyotype. The patient is currently in continuing first remission and complete donor chimerism 5 months post-PBSCT.
The majority of AML FAB M0 have cytogenetic abnormalities. Bene et al 4 showed that only 24% of 241 patients diagnosed as AML M0 have a normal karyotype, the most frequent aberrations were unbalanced, and the chromosomes 5, 7, 8 and 11 are the most frequently affected. The prognostic value of cytogenetic aberration in patients with AML is well known. On the other hand, coexpression of lymphoid-associated markers in AML is a common feature with an incidence ranging from 13 to 60%, with differences between children and adults. 5 Some authors reported that AML M0 is significantly associated with the coexpression of lymphoidassociated markers (ie CD4 or CD7). 6, 7 The incidence of CD5-positive AML is 3% in children and 4% in adults and is distributed similarly through all FAB types. 5, 7 The coexpression of lymphoidassociated markers does not seem to be associated with an adverse overall survival in these patients.
There are only few data published as case reports about a hypertriploid or near-tertraploid chromosome number in patients with AML. Lemez et al 8 reported a series of three cases of neartetraploid AML. They concluded that these genetically characterized cases reflect a distinct AML category with large blasts, expression of CD34, low growth of granulocyte-macrophage colony-forming cells in culture, the presence of a preleukaemic phase, a higher age and a poor prognosis. All patients reported in these series have a short overall survival, and two died soon after a low-dose chemotherapy. 8 Yeh et al 9 reported on a 43-year-old woman with AML M0 and a near-tetraploid chromosome number. Like the other patients, is woman died in neutropaenic phase after the induction therapy. Hypertriploid or near-tetraploid chromosome numbers in patients with AML M0 are very rare (this was the first case at our department), and to the best of our knowledge the coincidence of the coexpression of CD5 in such cases has never been reported in the past. Our patient achieved complete remission without any signs of the disease after first induction chemotherapy (normal female karyotype, normal blood count), which was consolidated with a sibling PBSCT. Owing to the worse prognosis of patients with hypertriploid or near-tetraploid AML described in the literature, an aggressive chemotherapy, including bone marrow transplantation carried out in these cases, should be initiated to improve the outcome of these patients.
C Kahl
